Nektar Therapeutics Reports Financial Results for the First Quarter of 2015

Therapeutics Reports Financial Results for the

FRANCISCO, Calif., April 30, 2015 -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first

quarter ended March 31, 2015.

and investments in marketable securities at March 31, 2015 were $325.8 million as compared to $262.8 million at December 31, 2014.

Our cash and investments in marketable securities at March 31, 2015 includes a $100.0 million milestone payment received from

AstraZeneca in Q1 2015 for the first commercial sale of Movantik (naloxegol) in the U.S.

recent U.S. launch of Movantik by AstraZeneca is progressing well and this first-in-class medicine to treat OIC is now being made

available in several European countries," said Howard W. Robin, President and Chief Executive Officer of Nektar. "In

the first quarter, we initiated enrollment for the SUMMIT-07 efficacy study of NKTR-181 in patients with chronic low back pain.

We are also finalizing preparations for our new cancer immunotherapy, NKTR-214, to enter clinical studies this year. With the

recent launch of Movantik and the anticipated approval of BAX 855 in Q4, we are beginning to see important new medicines emerging

from our late-stage pipeline that should drive Nektar's near-term revenue. Importantly, we have three additional partnered drug

candidates in Phase 3 which are expected to have data readouts in 2016 and should continue to build our revenue base in the future."

for the first quarter of 2015 was $108.8 million as compared to $19.8 million in the first quarter of 2014. The increase in revenue

in the first quarter of 2015 as compared to the first quarter of 2014 is due to the recognition of $90.0 million of the $100.0

million milestone payment from AstraZeneca following the first commercial sale of Movantik in the U.S. Revenue also included non-cash

royalty revenue, related to our 2012 royalty monetization, of $4.0 million and $5.8 million in the three months ended March 31,

2015 and 2014, respectively. This non-cash royalty revenue is offset by non-cash interest expense.

operating costs and expenses for the first quarter of 2015 were $65.8 million as compared to $56.2 million in the first quarter

of 2014. Total operating costs and expenses increased primarily as a result of increased research and development (R&D) expense.

expense in the first quarter of 2015 was $47.0 million as compared to $38.3 million for the first quarter of 2014. R&D expense

was higher in the first quarter of 2015 primarily due to the initiation of the Phase 3 efficacy study of NKTR-181 in patients

with chronic low back pain. Additionally, R&D expense in the first quarter of 2015 included costs related to the continued

production of devices for the ongoing Phase 3 studies of Amikacin Inhale, the ongoing Phase 3 study of NKTR-102 in breast cancer,

the ongoing Phase 1 study of NKTR-171, and IND enabling activities for NKTR-214 which will enter the clinic in 2015.

and administrative expense was $10.3 million in the first quarter of 2015 as compared to $9.9 million in the first quarter of

Q1 2015, net income was $33.8 million, or $0.26 basic earnings per share. This compared to a net loss of $46.2 million or ($0.37)

basic loss per share in Q1 2014.

#1001: "Phase III trial of etirinotecan pegol (EP) versus Treatment of Physician's Choice (TPC) in patients (pts) with

advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACON

study.", Perez, E., et al.

Abstract Session: "Breast Cancer-Triple-Negative/Cytotoxics/Local Therapy"

June 1, 2015, 3:12 p.m. - 3:24 p.m. Central Time

Call to Discuss First Quarter 2015 Financial Results

will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time today, Thursday,

release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and

Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available

for replay through Monday, June 1, 2015.

the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release,

or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website

as soon as practical after the conclusion of the conference call.

Therapeutics has a robust R&D pipeline in pain, oncology, hemophilia and other therapeutic areas. In the area of pain, Nektar

has an exclusive worldwide license agreement with AstraZeneca for MOVANTIK (naloxegol), the first FDA-approved once-daily

oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC),

in adult patients with chronic, non-cancer pain. The product is also approved in the European Union as MOVENTIG and is indicated

for adult patients with OIC who have had an inadequate response to laxatives. The AstraZeneca agreement also includes NKTR-119,

an earlier stage development program that is a co-formulation of MOVANTIK and an opioid. NKTR-181, a wholly-owned mu-opioid

analgesic molecule for chronic pain conditions, is in Phase 3 development. NKTR-171, a wholly-owned new sodium channel blocker

being developed as an oral therapy for the treatment of peripheral neuropathic pain, is in Phase 1 clinical development. In hemophilia,

BAX 855, a longer-acting PEGylated Factor VIII therapeutic is in Phase 3 development conducted by partner Baxter. A BLA for BAX

855 was filed by Baxter to the US FDA in December, 2014 and is currently under review. In anti-infectives, Amikacin Inhale is

in Phase 3 studies conducted by Bayer Healthcare as an adjunctive treatment for intubated and mechanically ventilated patients

with Gram-negative pneumonia.

technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies,

including AstraZeneca's MOVANTIK , UCB's Cimzia for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS

for hepatitis C and Amgen's Neulasta for neutropenia.

is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further

information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

is a trademark and MOVENTIG is a registered trademark of the AstraZeneca group of companies.

Note Regarding Forward-Looking Statements

press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act

of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan,"

"expect," "believe," "should," "may," "will" and similar references to future

periods. Examples of forward-looking statements include, among others, statements we make regarding the potential of MOVANTIK

(naloxegol), BAX 855, the future revenue potential from our collaboration partnerships, the timing of availability of future clinical

trial data from our collaboration partners, the timing of the expected start date of the clinical program for NKTR-214, and the

value and potential of our polymer conjugate technology and research and development pipeline. Forward-looking statements are

neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations

and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy

and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties,

risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results

may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking

statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking

statements include, among others, (i) the commercial potential of a new drug at the early stages of commercial launch, such as

MOVANTIK, is difficult to predict and will have a significant impact on our future results of operation and financial condition;

(ii) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application

of our technology platform to potential new drug candidates is therefore highly uncertain and unpredictable and one or more research

and development programs could fail; (iii) patents may not issue from our patent applications for our drugs (including MOVANTIK

and BAX 855) and drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses

from third parties may be required; and (iv) the outcome of any existing or future intellectual property or other litigation related

to our drugs and drug candidates and those of our collaboration partners including MOVANTIK and BAX 855. Other important risks

and uncertainties set forth in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February

26, 2015 and our Current Report on Form 8-K filed with the SEC on March 17, 2015. Any forward-looking statement made by us in

this press release is based only on information currently available to us and speaks only as of the date on which it is made.

We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time,

whether as a result of new information, future developments or otherwise.

Ruddock of Nektar Therapeutics